Surrozen, Inc.
NASDAQ:SRZN · NASDAQ Capital Market
-$1.14 today
Vol 0.20M · Avg 0.11M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:SRZN · Revenue to Net Income
Key Ratios
Analysis
$7.5M of revenue converted into -$342.6M of net income for the selected period. Gross margin is 99.7% and net margin is -10121.0%, showing how much revenue survives after costs and taxes. EPS is $-41.33, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.5M -67.4% | $10.7M | $0 -100.0% | $12.5M | $0 | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $537.0K | $0 -100.0% | $27.2M +733.0% | $3.3M -0.8% | $3.3M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $2.9M -72.4% | $10.7M +139.1% | -$27.2M -395.0% | $9.2M +380.0% | -$3.3M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 84.6% -15.4pp | 100.0% | — | 73.8% | — | 9.8% | 28.9% | 38.3% |
| Research & Development | $29.4M +39.0% | $21.1M -22.4% | $27.2M -26.4% | $37.0M +0.4% | $36.9M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $16.2M +7.6% | $15.1M -4.7% | $15.8M -20.3% | $19.8M +39.5% | $14.2M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $45.0M +24.4% | $36.2M +95.1% | $18.6M -65.4% | $53.6M +4.8% | $51.1M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $537.0K -62.8% | $1.4M -24.5% | $1.9M -2.3% | $2.0M -40.7% | $3.3M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$241.5M -288.7% | -$62.1M -51.0% | -$41.1M -20.8% | -$34.0M +33.7% | -$51.4M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -6945.3% -6362.3pp | -583.0% | — | -272.4% | — | 5.6% | 46.3% | 42.0% |
| Operating Income | -$42.1M -64.8% | -$25.5M +44.2% | -$45.8M -3.2% | -$44.3M +18.5% | -$54.4M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -1210.6% -970.9pp | -239.7% | — | -354.7% | — | 16.6% | 24.1% | 22.0% |
| Interest Income | $3.0M +78.4% | $1.7M -27.6% | $2.3M +199.6% | $781.0K +984.7% | $72.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$199.9M -425.8% | -$38.0M -1488.8% | $2.7M -67.2% | $8.3M +3343.2% | -$257.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$242.0M -280.8% | -$63.6M -47.7% | -$43.0M -19.5% | -$36.0M +34.1% | -$54.6M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -6960.8% -6364.2pp | -596.6% | — | -288.0% | — | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$242.0M -280.8% | -$63.6M -47.7% | -$43.0M -19.5% | -$36.0M +31.4% | -$52.5M | $4.9B | $4.8B | $4.7B |
| Net Margin | -6960.8% -6364.2pp | -596.6% | — | -288.0% | — | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$32 -49.4% | -$22 -1.6% | -$21 -37.2% | -$16 +33.5% | -$23 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$32 -49.4% | -$22 -1.6% | -$21 -37.2% | -$16 +33.5% | -$23 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $7.5M +155.0% | $2.9M +45.3% | $2.0M -12.8% | $2.3M -0.9% | $2.3M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $7.5M +155.0% | $2.9M +45.3% | $2.0M -12.8% | $2.3M -0.9% | $2.3M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Immix Biopharma, Inc.
NASDAQ:IMMX
$506.48M
Greenwich LifeSciences, Inc.
NASDAQ:GLSI
$343.91M
Opus Genetics, Inc.
NASDAQ:IRD
$335.63M
Agenus Inc.
NASDAQ:AGEN
$123.47M
Cognition Therapeutics, Inc.
NASDAQ:CGTX
$104.85M
Seer, Inc.
NASDAQ:SEER
$94.57M
Instil Bio, Inc.
NASDAQ:TIL
$51.20M
Tevogen Bio Holdings Inc.
TVGN
$43.63M
VistaGen Therapeutics, Inc.
VTGN
$22.67M
Atossa Therapeutics, Inc.
ATOS
$17.22M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does SRZN generate?
Surrozen, Inc. (SRZN) reported $3.48M of revenue in fiscal 2025.
Is SRZN profitable?
Surrozen, Inc. (SRZN) reported -$242,026,000.00 of net income, with a net margin of -6960.8%.
Explore More
Continue the stock analysis
Jump to another research area for this company.